7-[4-(4-methoxyphenyl)thiazol-2-yl]heptanoic acid | 847265-46-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 7-[4-(4-methoxyphenyl)thiazol-2-yl]heptanoic acid
• 英文别名: 7-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]heptanoic acid
• CAS: 847265-46-7
• 化学式: C₁₇H₂₁NO₃S
• 分子量: 319.425
• InChiKey: DRNZRMINFCRDGE-UHFFFAOYSA-N

物化性质

• 沸点：
  508.1±40.0 °C(Predicted)
• 密度：
  1.176±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-[4-(4-methoxyphenyl)thiazol-2-yl]heptanoic acid 在 羟胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 7-[4-(4-Methoxy-phenyl)-thiazol-2-yl]-heptanoic acid hydroxyamide
  参考文献：
  名称：

  A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units

  摘要：

  A series of structurally novel HDAC inhibitors, in which a hetero aromatic ring connects the spacer with the hydrophobic group, has been designed and synthesized. These new inhibitors are very potent in in vitro enzymatic assays and display antiproliferation activity against two human cancer cell lines. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.07.012
• 作为产物：
  描述：

  辛二酸单甲酯 在 劳森试剂 、 ammonium hydroxide 、 sodium hydroxide 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 苯 为溶剂， 反应 1.5h， 生成 7-[4-(4-methoxyphenyl)thiazol-2-yl]heptanoic acid
  参考文献：
  名称：

  A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units

  摘要：

  A series of structurally novel HDAC inhibitors, in which a hetero aromatic ring connects the spacer with the hydrophobic group, has been designed and synthesized. These new inhibitors are very potent in in vitro enzymatic assays and display antiproliferation activity against two human cancer cell lines. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.07.012

文献信息

• [EN] COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE<br/>[FR] COMPOSES, PROCEDES ET PREPARATIONS DESTINES A L'APPORT ORAL D'UN COMPOSE PEPTIDIQUE DE TYPE GLUCAGON (GLP-1) OU D'UN PEPTIDE AGONISTE DU RECEPTEUR 4 DE MELANOCORTINE (MC4)
  申请人：LILLY CO ELI

  公开号：WO2005019184A1

  公开（公告）日：2005-03-03

  The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.

  本发明涉及用于口服给荷GLP-1化合物或MC4激动剂肽的新化合物、方法和配方。
• Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
  申请人：Herr Robert Jason

  公开号：US20080214448A1

  公开（公告）日：2008-09-04

  The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.

  本发明涉及一种新型化合物、方法和配方，用于口服给药GLP-1化合物或MC4激动剂肽。
• COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE
  申请人：HERR Robert Jason

  公开号：US20100120876A1

  公开（公告）日：2010-05-13

  The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.

  本发明涉及一种新型化合物、方法和配方，用于口服给药GLP-1化合物或MC4激动剂肽。
• Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide
  申请人：Herr Robert Jason

  公开号：US08552039B2

  公开（公告）日：2013-10-08

  The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.

  本发明涉及一种新型化合物、方法和制剂，用于口服给药GLP-1化合物或MC4激动剂肽。
• COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE
  申请人：Emisphere Technologies, Inc.

  公开号：US20140031287A1

  公开（公告）日：2014-01-30

  The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.

  本发明涉及新型化合物、方法和配方，用于口服给药GLP-1化合物或MC4激动剂肽。